NEUROLOGY

Redefining AD management: Lecanemab introduces new formulation backed by 4 years of positive efficacy and safety data

19 Nov 2025

Cracks in the network: How vascular disease shapes the dementia burden

29 Sep 2025

Real-world long-term evidence paves the way for CGRP-pathway therapies in migraine prevention

30 Jun 2025

Longitudinal assessment of MCI and dementia in an essential tremor cohort

08 Jul 2024

Real-world effectiveness of fremanezumab in migraine prevention

08 Apr 2024

Examining real-world effectiveness of fremanezumab in migraine prevention: Insights from the 3rd interim analysis of PEARL

01 Jan 2024

Where clopidogrel fails: The struggle with CYP2C19 polymorphisms in the treatment of neurovascular diseases

03 Jan 2024

Navigating anticoagulation strategies for preventing recurrent events in NVAF patients with ischemic stroke despite DOAC

30 Jun 2023

Ante-mortem CSF biomarkers for the early detection of AD

24 May 2023

Connecting the dots between Parkinson’s disease and rheumatoid arthritis

12 Jul 2023

Real-world DATA confirm the effectiveness and tolerability of brivaracetam in patients with focal-onset seizures

01 Mar 2023

Brivaracetam as a suitable antiepileptic treatment with promising efficacy and safety

23 Jan 2023

Neurodegeneration and PSE risk factors in addition to new development of personalized treatments

17 Jan 2023

Diagnosis and treatment of depression in pediatric and adult epilepsy

16 Sep 2022

Improving multiple sclerosis management in Hong Kong through integrative Western-Chinese medicine approach

16 Aug 2021

Interview with the Expert: Dr. Peter YM Woo - Glioblastoma Multiforme (GBM) Treatment with Combination of TTFields and Chemotherapy: When and Where to Implement TTFields in the Clinical Setting?

07 Jun 2021

Intracranial atherosclerotic disease: Stroke mechanisms, management and recurrence

30 Dec 2019
Expert Insight View All

Cracks in the network: How vascular disease shapes the dementia burden

Dementia affects over 57 million people globally, with numbers projected to triple by 2050 due to population aging. While Alzheimer’s disease (AD) dominates clinical focus and public attention, vascular dementia (VaD), the second most common subtype, poses its own set of diagnostic challenges, and a compelling opportunity for prevention through effective vascular risk management and multidisciplinary care.
29 Sep 2025
thumb

Dr. Mohamad Imran Idris

Consultant Neurologist
Sunway Medical Centre,
Selangor, Malaysia

Improving multiple sclerosis management in Hong Kong through integrative Western-Chinese medicine approach

Multiple sclerosis (MS) is among the most common central nervous system (CNS) inflammatory demyelinating diseases with an estimated global prevalence of 1 in 3,000 people in 2020.1 Although MS is regarded as relatively uncommon in the Asia Pacific Region and even rarer in Hong Kong with a local prev
16 Aug 2021
thumb

Dr. Alexander Yuk-lun LAU

Specialist in Neurology
Clinical Associate Professor (Honorary),
Department of Medicine and Therapeutics Medical Director,
Hong Kong Institute of Integrative Medicine,
The Chinese University of Hong Kong
Conference update View All
thumb

AAN 2025

Apr 5-9, 2025 | San Diego, United State 

Meeting Highlight View All

Redefining AD management: Lecanemab introduces new formulation backed by 4 years of positive efficacy and safety data

NEUROLOGY
19 Nov 2025
Research Spotlight View All

Navigating anticoagulation strategies for preventing recurrent events in NVAF patients with ischemic stroke despite DOAC

The increasing incidence of ischemic stroke in patients receiving direct oral anticoagulants (DOACs) highlights the heightened risk of subsequent ischemic events.1 Yet, the effectiveness and safety of antithrombotic regimens following this condition remain uncertain.1 In this investigation, patient outcomes were compared between those receiving DOACs with or without an alternative antithrombotic regimen, and the risk factors for recurrent ischemic stroke while on anticoagulation were identified.1 The 6-year study period, spanning January 1, 2015 to December 31, 2020, included 45,946 non-valvular atrial fibrillation (NVAF) patients administered DOACs for stroke prevention.1 Among them, 2,908 patients experienced an ischemic stroke despite the DOAC treatment, and 2,337 NVAF patients were included in the final analysis.1 The findings demonstrated that switching to warfarin (aHR=1.96; 95% CI: 1.27-3.02; p=0.002) or another DOAC(aHR=1.62; 95% CI: 1.25-2.11; p<0.001) was associated with an elevated risk of recurrent ischemic stroke compared with maintaining the sameDOAC therapy.1 Furthermore, the addition of an antiplatelet agent did not exhibit a reduced risk of recurrent ischemic stroke.1 The risk factors of recurrent ischemic stroke include diabetes mellitus (DM), concurrent cytochrome P450/P-glycoprotein (CYP/P-gp) modulators, and large artery atherosclerotic disease (LAD).1
30 Jun 2023
thumb

Professor Leung Wai-Hong Thomas

Head of Division of Neurology
(Academic Affairs),
Lee Quo Wei Professor of Neurology
Assistant Dean (Education),
Faculty of Medicine,
The Chinese University of Hong Kong
thumb

Dr. Ip, Yiu-Ming Bonaventure

Assistant Professor,
Department of Medicine and Therapeutics,
The Chinese University of Hong Kong

Neurology. 2023.

Ip YMB, et al. Association of Alternative Anticoagulation Strategies and Outcomes in Patients With Ischemic Stroke While Taking a Direct Oral Anticoagulant.
Infographics

Real-world effectiveness of fremanezumab in migraine prevention
08 Apr 2024
News & perspective View All

Advancements in Alzheimer's disease diagnostic recommendations: The 2024 DETeCD-ADRD guideline

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that presents significant diagnostic challenges due to its complex symptoms, which often overlap with other cognitive disorders.1 Early and accurate diagnosis is essential for timely interventions and improved patient outcomes. Recently, the Alzheimer’s Association released updated, evidence-based guidelines for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer’s Disease and Related Disorders (DETeCD-ADRD).2-5 This marks the first revision since 2001 for specialists and introduces guidelines specifically for primary care physicians, aiming to enhance the evaluation and diagnosis of cognitive decline.2-5
14 Apr 2025

Limited efficacy of prothrombin complex concentrate in managing DOAC-associated ICH

Direct oral anticoagulants (DOACs) have revolutionized the management of atrial fibrillation (AF), significantly reducing the risk of ischemic stroke.1 However, the associated risk of intracerebral hemorrhage (ICH), though rare, remains a serious concern with high mortality rates.2 To mitigate the i
03 Oct 2024
Case review View All
NEUROLOGY

Where clopidogrel fails: The struggle with CYP2C19 polymorphisms in the treatment of neurovascular diseases

03 Jan 2024
Features

Real-world long-term evidence paves the way for CGRP-pathway therapies in migraine prevention

For decades, migraine prevention relied on nonspecific, off-label drugs, often lacking large-scale clinical trials to confirm their efficacy, safety, or tolerability.1-3 This has resulted in high discontinuation rates.2,3 However, the introduction of calcitonin gene-related peptide (CGRP) pathway-ta
30 Jun 2025
thumb

Dr. Sait Ashina

Assistant Professor of Neurology and Anesthesia,
Department of Neurology and Anesthesia,
Critical Care and Pain Medicine,
Harvard Medical School
Boston, United States